EICHORPublic-registry trials using 140mg Brodalumab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
140mg Brodalumab appears in 1 registered trial Eichor's radar has found, sponsored by MedDerm Associates, the most recent registered as Phase 3, with a planned enrollment of 15. Registered timeline: 2012–2017. The registry holds 2,534 registered studies for Psoriasis.
| Trial | Sponsor | Condition | Phase | Sites |
| Study to Evaluate Broadlumab vs Placebo and Ustekinumab | MedDerm Associates | Psoriasis | PHASE3 | 1 |
| Status | Terminated · planned start 2012-08 |
| Primary completion | 2017-06 |
| Enrollment target | 15 participants |
| Design | Randomized · Single Group · Phase 3 · 4 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 1 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT02786732.
| First registered study | February 2010 — NCT01059448 (Amgen) |
| Registered studies matching this name | 6 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 2,534 registered studies for Psoriasis. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Psoriasis studies · Weekly briefs
